<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04149938</url>
  </required_header>
  <id_info>
    <org_study_id>SCI-LIDO-PK-002A</org_study_id>
    <nct_id>NCT04149938</nct_id>
  </id_info>
  <brief_title>Comparative Pharmacokinetic Study of Lidocaine Patch 1.8% (ZTlido™) and Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects</brief_title>
  <official_title>Phase 1, Randomized Comparative Pharmacokinetic Study of Lidocaine Patch 1.8% (ZTlido™) and Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scilex Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scilex Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the comparative single-dose pharmacokinetics
      (bioequivalence) of lidocaine patch 1.8% (investigational product) versus Lidoderm®
      (lidocaine patch 5%,reference product).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2016</start_date>
  <completion_date type="Actual">October 27, 2016</completion_date>
  <primary_completion_date type="Actual">October 27, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax) of lidocaine</measure>
    <time_frame>0, 2, 4, 6, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24, 48 hours post-dose</time_frame>
    <description>Peak plasma concentration of lidocaine after application of 3 patches for 12 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Plasma-Concentration Time Curve (AUC) from Time 0 to Time 48 hours</measure>
    <time_frame>0, 2, 4, 6, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24, 48 hours post-dose</time_frame>
    <description>Area under the plasma concentration versus time curve from 0 to 48 hours of lidocaine in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Plasma-Concentration Time Curve (AUC) from Time 0 to Time Infinity</measure>
    <time_frame>0, 2, 4, 6, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24, 48 hours post-dose</time_frame>
    <description>Area under the plasma concentration versus time curve from 0 to infinite time of lidocaine in plamsa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent dose</measure>
    <time_frame>0 to 12 hours</time_frame>
    <description>Apparent dose of delivered lidocaine assessed by calculating the quantity of lidocaine in the patch as manufactured minus the quantity recovered from the used patch after 12 hours of wear and adhesive residue remaining on skin and on the product liner and envelope</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lidocaine Patch (Sequence AB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received all study treatments: ZTlido and Lidoderm. On Day 1 (Period 1), three ZTlido lidocaine topical systems were applied to the skin on the back for 12 hours. On Day 8 (Period 2), three Lidoderm lidocaine patches were applied to the skin on the back for 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine Patch (Sequence BA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received all study treatments: ZTlido and Lidoderm. On Day 1 (Period 1), three Lidoderm lidocaine patches were applied to the skin on the back for 12 hours. On Day 8 (Period 2), three ZTlido lidocaine topical systems were applied to the skin on the back for 12 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine topical system 1.8%</intervention_name>
    <arm_group_label>Lidocaine Patch (Sequence AB)</arm_group_label>
    <arm_group_label>Lidocaine Patch (Sequence BA)</arm_group_label>
    <other_name>Lidocaine patch 1.8%</other_name>
    <other_name>ZTlido</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine patch 5%</intervention_name>
    <arm_group_label>Lidocaine Patch (Sequence AB)</arm_group_label>
    <arm_group_label>Lidocaine Patch (Sequence BA)</arm_group_label>
    <other_name>Lidoderm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Must be healthy based on medical history, laboratory work, and physical exam

          -  Be ≥18 and ≤65 years of age

          -  Females of childbearing potential must not be pregnant and be using an acceptable form
             of birth control

          -  Must be free of any systemic or dermatologic disorder

        Key Exclusion Criteria:

          -  Use of prescription medication within 14 days or over-the-counter products within 7
             days prior to study medication

          -  Current use of opioids

          -  Known hypersensitivity or allergy to any of the components of the product formulations

          -  Any serious illness in the 4 weeks preceding the beginning of treatment that resulted
             in missed work or hospitalization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip LaStella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TKL Research, Inc.</affiliation>
  </overall_official>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 31, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2019</study_first_posted>
  <last_update_submitted>November 1, 2019</last_update_submitted>
  <last_update_submitted_qc>November 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

